+39 02 610346.1 - info@newron.com



We aim to build a leading Central Nervous System (CNS) company that searches, develops and commercializes innovative drugs, with a special focus on rare diseases. Our global growth strategy has three elements:                          

  1. Maximize Xadago’s market potential

Xadago® is the first New Chemical Entity in a decade approved in Europe and the U.S.  for the treatment of Parkinson’s disease (PD). The product is commercialized in a number of European markets as well as in the USA. Our partners Zambon and Meiji Seika Pharma are working towards global approval.

A study with Xadago to demonstrate the reduction of dyskinesia in PD patients with Levodopa Induced Dyskinesia (LID) is in planning together with our partner Zambon. If prior evidence of Xadago’s benefits in this area of high unmet need in the PD therapy is confirmed, Xadago’s commercial potential could be significantly enhanced.

Newron receives milestone and royalty payments from sales of Xadago® in PD.

  1.  Leverage CNS expertise; focus on treating inadequate/non-response in schizophrenia  

Newron is developing Evenamide as add-on therapy for the treatment of positive symptoms of schizophrenia, with the additional potential to improve life of patients who are treatment resistant to clozapine, an orphan-like indication.  

Newron plans to partner opportunities directed at larger markets when offered the best return to Newron’s shareholders.

  1. Partner non-core assets and in-license strategically relevant assets

Partnering is an important part of our strategy. We are actively engaging potential partners about our innovative pipeline of novel compounds to enable our products to be brought to market by companies with the best expertise. In addition, we are continuously searching for strategically relevant assets to in-license and expand our clinical portfolio.